[Cell therapy for myocardial infarction].
The review discusses cell therapy; one of the most promising approaches to myocardial infarction treatment. The possibility to use cell material of various origins is analyzed. The review sums up data on the application of fetal and neonatal cardiomyocytes, myoblasts, bone marrow mononuclear fraction, hematopoietic and mesenchymal stem cells (MSX) as cell therapy agents. The conclusion is made that MSC are promising cell material for myocardial infarction therapy. MSC are able to migrate to the injured area, differentiate into myocardial lineage. They produce a wide range of factors that stimulate angiogenesis and increase viability of cells, including cardiomyocytes.
Krugliakov
P V
PV
Sokolova
I B
IB
Polyntsev
D G
DG
D000818:Animals; D016026:Bone Marrow Transplantation; D017690:Cell Transplantation / Q000379:methods*; D005333:Fetus / Q000166:cytology; D006801:Humans; D007231:Infant, Newborn; D045164:Mesenchymal Stem Cell Transplantation; D032448:Myoblasts, Skeletal / Q000637:transplantation; D009203:Myocardial Infarction / Q000628:therapy*